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Purpose
A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers.
The aim of the present study is to determine the incidence of localized and advanced STS
in Korean patients, their treatment patterns, and the survival of patients by disease status. 
Materials and Methods
The STS patient cohort was defined using National Health Insurance Service medical data
from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates
(Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different
algorithms to the STS cohort containing localized and advanced STS cases.  
Results
A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized
STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 per-
son-years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-
years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS,
82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients
(49.98%) received anthracycline-containing chemotherapy as initial treatment after diag-
nosis.
Conclusion
This study provides insights into localized and advanced STS epidemiology, treatment pat-
terns and outcomes in Korea, which could be used as fundamental data in improving clinical
outcomes of STS patients in the future.
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Introduction
Soft tissue sarcoma (STS) refers to a rare cancer which 
accounts for 1% of all malignant tumors [1]. Risks for sar-
coma are not well understood and its development can be
divided into environmental exposures, genetic susceptibility,
and an interaction between the two [2]. The annual incidence
rate ranges from 1.8 to 5 cases per 100,000 persons worldwide
[1,3,4]. Every year, new cases reach an average of 12,310 in
the United States [5], 23,574 in the European Union [6], and
412 in Korea [7,8]. STS is a heterogeneous group of cancerous
tumors, comprised of more than 50 histological subtypes that
develop from soft tissues of the body (e.g., fat, muscles, nerve
tissues, deep skin tissues, visceral non-epithelial tissues) [9]
with distinct molecular subtypes [10].
The 5-year survival rate of STS patients is about 50%, with
high variability depending on factors such as stage, size, pri-
mary site, metastasis, and tissue type of tumors [4]. About
40% to 50% of STS patients experience metastasis [11]. In 
patients with localized STS, surgery is the standard treat-
ment, and radiotherapy and chemotherapy can be applied
before and after the surgery [3]. Chemotherapy and/or 
radiotherapy can be used as the first treatment for patients
not amenable to curative treatment with surgery. However,
treatment modalities for incurable patients are very limited.
Doxorubicin and ifosfamide are frequently used as first line
treatment, either as monotherapy or as combination therapy
[4,12]. Radiotherapy is also broadly used to treat metastatic
STS patients [4]. Individualized treatments for advanced STS
patients according to a variety of histologic and molecular
subtypes of this disease should be encouraged, and the
choice of chemotherapy should be adapted to the site of the
disease and subtype [13]. Little, however, is known about
real-world treatment patterns for advanced STS cancer. A
deeper understanding of currently used treatments is needed
to develop of new therapeutic protocols and treatment 
objectives.
The objectives of this study are to describe the incidence
of localized and advanced STS cases in Korea, to investigate
the epidemiological and clinical characteristics of STS pati-
ents, to analyze treatment patterns, and to estimate the sur-
vival rate of STS patients according to treatment type.
Materials and Methods
1. Data source
Medical data from the National Health Insurance Service
(NHIS) in Korea was used. In Korea, around 97% of citizens
are either national health insurance subscribers or depend-
ents, and the remaining 3% are medical aid beneficiaries. The
NHIS keeps the claim data of the entire Korean population,
consisting of around 50 million people. The Big Data Steering
Department was established in 2014 [14], which covers data
from 2002 to 2015 and includes the NHIS. The data extracted
for this research included patient information (age, sex),
treatment records, main/sub-disease codes (primary/sec-
ondary disease) and mortality. 
2. STS patient cohort definition 
To define the STS cohort, three inclusion/exclusion criteria
were applied: (1) all individuals with a first STS diagnoses
as main disease code or first sub-disease code from 2007 to
2014 who were 18 years of age or older at the time of diag-
nosis (STS Initial Cases) were included; (2) individuals with
a cancer diagnosis code in the previous 5-year period (2002-
2006) were excluded since they might have had multiple pri-
mary cancers or other primary cancers with metastases to
soft tissue; and (3) patients who survived more than 1 year
without any relevant surgery, radiotherapy and chemother-
apy records after first STS diagnosis were excluded. Some
10,091 patients were initially coded but finally excluded 
because they might be suspected to have sarcoma but this
was not confirmed by pathologic analysis or they might be
prevalent cases who had been diagnosed and treated before
the index period. The International Classification of Diseases,
10th revision (ICD-10) diagnosis codes used for STS diagno-
sis are listed in S1 Table. Patients with diagnostic codes C40
and C41 were not included in the STS patient cohort as these
codes were used both for chondrosarcoma and osseocarti-
laginous sarcoma, and therefore it was not possible to distin-
guish chondrosarcoma cases using these codes.
Subgroups were defined using an algorithm based on
treatment type (surgery, radiotherapy, chemotherapy), treat-
ment period and survival. The STS cohort was classified into
five subgroups: (1) patients who received only surgery
(surgery, OP), (2) patients who received only radiotherapy
(radiotherapy, RT), (3) patients who received surgery and
pre/postoperative treatment (Pre-OP/Post-OP), (4) patients
who received only chemotherapy with or without radiother-
apy (systemic treatment, CTx/CCRT), or (5) those who died
within a year of diagnosis (clinical deterioration < 1 year, CD)
regardless of treatments. Regarding the clinical deterioration
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CD-OP (n=327)
CD-RT (n=79)
CD-Pre/Post-OP (n=333)
CD-CTx/CCRT (n=299)
CD-No Tx (n=355)
Soft tissue sarcoma initial cases (n=27,098, annual avg. 3,387)
Soft tissue sarcoma cohort (n=7,813, annual avg. 977)
Surgery (OP)
n=2,569
(annual avg. 321)
Radiotherapy (RT)
n=471
(annual avg. 59)
Systemic therapy
(CTx/CCRT)
(annual avg. 82)
Post-Obs
n=52
(annual avg. 7)
Post-Txa)
n=60
(annual avg. 8)
Surgery with other
treatment
n=2,723
(annual avg. 340)
Preoperative treatment
(Pre-OP)
n=2,611
(annual avg. 326)
Postoperative treatment
(Post-OP)
n=112
(annual avg. 14)
Clinical deterioration (CD)
n=1,393
(annual avg. 174)
Exclusion criteria (n=19,285, annual avg. 2,411)
  Multiple primary cancer patients (n=9,194, annual avg. 1,149)
  No relevant treatment but survived over 1 year (n=10,091, annual avg. 1,262)
  Relevant treatment: relevant surgery, radiotherapy, or chemotherapy
Pre-Obs
n=1,215
(annual avg. 152)
Pre-Txa)
n=1,396
(annual avg. 175)
Pre-Sys CTx
n=189
Pre-Local Tx
n=1,207
*White shaded boxes refer to advanced STS patients
Post-Sys CTx
n=7
Post-Local Tx
n=53
Fig. 1. Taxonomy of soft tissue sarcoma (STS) patients by treatment patterns. Localized and advanced cases were defined
using a diagnostic algorithm. OP, only surgery; RT, only radiotherapy; Pre/Post-OP, surgery in combination with pre/post-
operative treatment; CTx/CCRT (systemic treatment), chemotherapy±radiotherapy; CD (clinical deterioration < 1 year), 
patients who died within a year of diagnosis; Pre-Obs, patients who received surgery with preoperative treatment followed
by observation; Pre-Tx, patients who received surgery with preoperative treatment followed by any treatment for cancer
(chemotherapy, radiotherapy or surgery) 1 year after the initial surgery; Pre-Sys CTx, patients who received surgery with
preoperative treatment followed by systemic chemotherapy 1 year after the initial surgery; Pre-Local Tx, patients who recei-
ved surgery with preoperative treatment followed by local treatments 1 year after the initial surgery; Post-Obs, patients who
received surgery with postoperative treatment followed by observation; Post-Tx, patients who received surgery with post-
operative treatment followed by any treatment for cancer (chemotherapy, radiotherapy or surgery) 1 year after the initial
surgery; Post-Sys CTx, patients who received surgery with postoperative treatment followed by systemic chemotherapy 1
year after the initial surgery; Post-Local Tx, patients who received surgery with postoperative treatment followed by local
treatments 1 year after the initial surgery; CD-OP, patients who received only surgery and died within a year of diagnosis;
CD-RT, patients who received only radiotherapy and died within a year of diagnosis; CD-Pre/Post-OP, patients who received
surgery with pre/postoperative treatment and died within a year of diagnosis; CD-CTx/CCRT, patients who received sys-
temic chemotherapy and/or radiotherapy and died within a year of diagnosis; CD-No Tx, patients who did not receive any
treatment and died within a year of diagnosis. a)1 Year; the 1-year period was chosen because in clinical practice adjuvant
therapy usually lasts about 1 year after surgery in Korea.
1382 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2019;51(4):1380-1391
group, those patients were separately categorized because it
was unclear whether mortality resulted from tumor progres-
sion or other causes. Pre-OP and Post-OP were subdivided
into the patients who received surgery with pre/postopera-
tive treatment followed by observation (Pre-Obs and Post-
Obs) or who received surgery with pre/postoperative treat-
ment followed by any treatment for cancer (chemotherapy,
radiotherapy or surgery) 1 year after the initial surgery (Pre-
Tx and Post-Tx). The 1-year period was chosen because in
clinical practice adjuvant therapy usually lasts about 1 year
after surgery in Korea. Pre-Tx and Post-Tx were subdivided
into patients who received a local treatment (Pre-Local Tx
and Post-Local Tx) and those who received systemic chemo-
therapy (Pre-Sys CTx and Post-Sys CTx).  
Overall, we defined localized STS as follows: only local
treatment (OP and RT), surgery combined with pre/postop-
erative treatment followed by observation (Pre-Obs and Post-
Obs). Advanced STS was defined as: only systemic treatment
after diagnosis (CTx/CCRT) and rapid clinical deterioration
within 1 year (CD), adding new treatment lasting longer 
( 1 year) than usual adjuvant treatment (Pre-Tx and Post-
Tx).  
3. Statistical analysis 
Descriptive analyses were conducted on patient demo-
graphics and clinical characteristics/medical resources, as
well as treatment patterns. STS incidence was calculated for
100,000 people using mid-year Korean Statistical Information
Service [7] population data from 2007-2014. Anatomical loca-
tions of tumors based on ICD-10 codes were also analyzed.
Comorbidities were defined as diseases for which a claim
was made under the main or sub-disease code based on ICD-
10 codes related to the Charlson comorbidity index within
three years prior to the STS diagnosis. Treatment patterns
were analyzed based on the initial chemotherapy after diag-
nosis.
The survival curve was estimated using Kaplan-Meier
product-limit estimator method; median survival time and
5-year survival rate were calculated. The survival period of
STS patients is the period from the date of the first diagnosis
to the date of death. Patients were censored if they were still
alive at the end of the follow-up period (December 31, 2015). 
SAS ver. 9.2 (SAS Institute Inc., Cary, NC) was used for
data management, statistical analysis, and plotting results.
Table 1.  Baseline characteristics by subgroup
Variable Total STS Curable STS Advanced STS(n=7,813) (n=4,307) (n=3,506)
Age (yr) 54.5±16.2 53.2±16.0 56.1±16.4                              
Median (min-max) 55 (18-101) 53 (18-97) 57 (18-101)
Distribution by age (yr)
18-29 648 (8.3) 377 (58.2) 271 (41.8)
30-39 807 (10.3) 504 (62.5) 303 (37.6)
40-49 1,433 (18.3) 883 (61.6) 550 (38.4)
50-59 1,777 (22.7) 972 (54.7) 805 (45.3)
60-69 1,537 (19.7) 771 (50.2) 766 (49.8)
 70 1,611 (20.6) 800 (49.7) 811 (50.3)
Sex
Male 3,740 (47.9) 2,102 (56.2) 1,638 (43.8)
Female 4,073 (52.1) 2,205 (54.1) 1,868 (45.9)
Initial diagnosis setting
General hospital 7,354 (94.1) 4,060 (55.2) 3,294 (44.8)
Hospital 249 (3.2) 132 (53.0) 117 (47.0)
Clinic 209 (2.7) 115 (55.0) 94 (45.0)
Oriental clinic 1 (0.0) 0 ( 1 (0.0)
Comorbidities 504 (6.5) 224 (5.2) 280 (8.0)
Cardiovascular disease 24 (0.3) 10 (0.2) 14 (0.4)
Cerebrovascular disease 35 (0.5) 18 (0.4) 17 (0.5)
Diabetes 186 (2.4) 101 (2.4) 85 (2.4)
Liver disease 142 (1.8) 57 (1.3) 85 (2.4)
Others 129 (1.7) 46 (1.1) 83 (2.4)
Values are presented as mean±standard deviation or number (%). 
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4. Ethical statement
The study was approved by the institutional review board
at Yonsei University Graduate of Public Health (IRB Num-
ber: 2-1040939-AB-N-01-2016-421-01). The informed consent
was waived as the NHIS database is anonymized in adher-
ence to strict confidentiality guidelines.
Results
1. Patient characteristics
During the 8-year study period, from 2007 to 2014, the STS
patient cohort was established with a total of 7,813 patients
(Fig. 1). The demographic characteristics of localized and 
advanced STS patients at the time of initial diagnosis are
shown in Table 1. The STS patients had an average initial 
diagnosis age (standard deviation) of 54.5±16.2 years. The
most populous age group was 50-59 years (22.7%), about half
were females (52.1%) and the initial diagnosis setting was a
general hospital (94.1%). The average age of the advanced
STS patients was 56.1±16.4 years, slightly higher than that of
the localized STS patients (53.2±16.0 years). The percentage
of advanced STS in the > 60 years age group was significantly
higher than that in the 18-59 years age group (p < 0.001).
More than 90% of both localized and advanced STS patient
groups were first diagnosed in a general hospital.
Only 504 out of 7,813 patients in the STS cohort had 
co-morbid conditions (6.5%): 224 in the localized STS patient
group (5.2%) and 280 in the advanced STS patient group
(8.0%), based on the Charlson comorbidity index (Table 1).
The most frequent co-morbidity among localized STS pati-
ents was diabetes (2.4%). For advanced STS patients, the
most common comorbidities were diabetes (2.4%) and liver
diseases (2.4%).
2. Incidence and distribution of STS patients
There were 3,506 patients with advanced STS (44.9%) and
4,307 patients with localized STS (55.1%) in the STS cohort
(Table 1). As sensitivity analyses, the numbers were recalcu-
lated using a 6- and 9-month period after the initial treatment
as the time to define a case of advanced STS if a new treat-
ment was received. The number of patients did not show a
significant change, with 49.49% of patients at 6 months and
46.81% of patients at 9 months. Annual incidence cases of 
advanced STS decreased from 459 in 2009 to 397 in 2014,
whereas that of localized STS increased steadily from 424 in
2009 to 743 in 2014, leading to the overall increase in annual
incidence cases of total STS (Fig. 2). Annual incidence cases
by modalities are shown in S2 Table. 
STS incidence was calculated for 100,000 people using mid-
No
. o
f c
as
es
1,400
0
200
400
600
800
1,200
2007
Year of diagnosis
2009 20142010 2011 2012 20132008
1,000
Total STS
Advanced STS
Curable STS
428
332 387
426 459
424 480
503
760 813
883
983 1,012
1,175
1,047
1,140
474
538
474
573
503
672
397
743
Fig. 2.  Annual incidence cases by subgroup. STS, soft tis-
sue sarcoma.
No
. o
f c
as
es
1,600
2,000
1,800
0
400
600
800
200
1,000
1,400
< 30
Age (yr)
40-49 ≥ 7050-59 60-6930-39
1,200
Total STS
Advanced STS
Curable STS
648
1,777
1,537 1,611
58%
42%
62%
38%
62%
38%
45%
50%
50% 50%
50%
55%
807
1,433
Fig. 3.  Incidence cases by age and distribution by sub-
group. STS, soft tissue sarcoma.
No
. o
f c
as
es
 
pe
r 1
00
,00
0 p
eo
pl
e
8
0
2
3
4
1
5
7
18-29
Age (yr)
40-49 ≥ 7050-59 60-6930-39
6
Male
Female
Overall
Fig. 4.  Incidence rate by sex and age.
1384 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2019;51(4):1380-1391
year Korean Statistical Information Service population data
from 2007-2014. The total incidence of STS in the Korean pop-
ulation was 2.49 per 100,000 person-years (Table 2). A higher
incidence was found in the “70 or older group” (5.64 per
100,000 person-years) and a lower incidence in the “18-29
group” (1.07 per 100,000 person-years). The incidence of 
localized STS was higher in all age groups, except in patients
of 70 years or older. STS incidence increased with age. Fur-
thermore, females showed a slightly higher incidence of total
STS (females 2.57 per 100,000 person-years vs. males 2.41 per
100,000 person-years), localized STS (females 1.39 per 100,000
person-years vs. males 1.36 per 100,000 person-years) and
advanced STS (females 1.18 per 100,000 person-years vs.
males 1.06 per 100,000 person-years) groups. 
If the incidence cases were analyzed by age and subgroup,
the proportion of localized STS was higher than that of 
advanced STS in all age subgroups except the “60-69” and
“70 or older” groups (Fig. 3). If the incidence rate of total STS
was analyzed by sex and age, the incidence rate of males was
higher than that of females in the “18-29,” “60-69,” and “70
or older” groups (Fig. 4). A similar trend was shown in 
localized STS. However, in advanced STS, the incidence rate
of males was higher than that of females in the “18-29,” “30-
39,” and “70 or older” groups (Table 2).
3. Anatomical locations of tumors in STS patients
Anatomical locations of tumors based on ICD-10 codes
were analyzed (Table 3). The main location for the total STS
group was in “other connective and soft tissues” (C49xx,
67.3%) and the second main location was in “retroperi-
toneum and peritoneum” (C48xx, 24.5%), while the remain-
ing locations (C47xx, C223, C224, and C542) represented
minor figures (< 10%). This distribution pattern was also 
observed in the localized STS group. However, the advanced
STS group showed that tumors were located in different
areas (C49xx, 58.6%; C48xx, 31.5%). 
4. Categorizing of STS patient cohort
The STS patient cohort contained localized STS and advan-
ced STS cases (shaded boxes in Fig. 1). The algorithm divided
the STS patient cohort into five different, mutually exclusive
groups, namely, patients with chemotherapy before or after
surgery (Pre-OP or Post-OP group, 2,723 patients; 34.9%), 
patients with only surgery (OP, 2,569 patients; 32.9%), pati-
Age group (yr)
Total STS Curable STS Advanced STS
Total Male Female Total Male Female Total Male Female
18-29 1.07 1.16 0.96 0.62 0.65 0.59 0.45 0.51 0.38
30-39 1.22 1.21 1.23 0.76 0.73 0.79 0.46 0.47 0.44
40-49 2.06 1.78 2.35 1.27 1.12 1.43 0.79 0.66 0.93
50-59 3.22 3.04 3.40 1.76 1.65 1.87 1.46 1.39 1.52
60-69 4.65 4.75 4.56 2.33 2.51 2.17 2.32 2.24 2.39
 70 5.64 6.94 4.86 2.80 3.71 2.25 2.84 3.22 2.61
Total 2.49 2.41 2.57 1.37 1.36 1.39 1.12 1.06 1.18
STS, soft tissue sarcoma.
Table 2. STS incidence rate (per 100,000) by sex and age group
Table 3.  STS anatomical locations of tumor
ICD-10 code Total STS Curable STS Advanced STS(n=7,813) (n=4,307) (n=3,506)
C49xx (other connective and soft tissues) 5,255 (67.3) 3,199 (74.3) 2,056 (58.6)                          
C48xx (retroperitoneum and peritoneum) 1,910 (24.5) 806 (18.7) 1,104 (31.5)
C47xx (peripheral nerves and autonomic nervous system) 338 (4.3) 191 (4.4) 147 (4.2)
C542 (myometrium) 303 (3.9) 160 (3.7) 143 (4.1)
C223 (hemangiosarcoma of liver, Kupffer cell sarcoma) 91 (1.2) 13 (0.3) 78 (2.2)
C224 (other liver sarcoma) 54 (0.7) 10 (0.2) 44 (1.3)
Values are presented as number (%). STS, soft tissue sarcoma; ICD-10, International Classification of Diseases, 10th revision.
VOLUME 51 NUMBER 4 OCTOBER 2019 1385
Hyo Song Kim, Advanced Soft Tissue Sarcoma in Korea
ents who died within 1 year of diagnosis due to clinical dete-
rioration (CD, 1,393 patients; 17.8%), patients who under-
went chemotherapy only or chemotherapy with radiother-
apy (systemic treatment group; CTx/CCRT, 657 patients;
8.4%), and patients who underwent only radiotherapy (RT,
471 patients; 6.0%). 
Pre-OP or Post-OP patients (34.9%) were further classified
into the advanced STS group if they received new treatments
(chemotherapy, radiotherapy or surgery) more than 1 year
after the initial surgery. Patients who were still under care 1
year after the initial surgery but in which only clinical obser-
vation was provided were categorized as localized STS. Pre-
OP or Post-OP patients were divided into patients who
received chemotherapy before (Pre-OP, 2,611 patients) or
after surgery (Post-OP, 112 patients). The number of patients
who received surgery and postoperative treatment and went
under observation without additional treatment was 52
(Post-Obs, 0.7%). The number of patients who were just 
observed with no additional treatment after preoperative
treatment and surgery was 1,215 (Pre-Obs, 15.6%) and the
number of patients who began a new treatment 1 year after
surgery and postoperative treatment was 60 (Post-Tx, 0.8%).
Of these, seven patients (Post-Sys CTx, 0.1%) were prescribed
chemotherapy as a new treatment 1 year after surgery, and
53 patients (Post-Local Tx, 0.7%) underwent local treatment
(surgery/surgery and radiotherapy). A total of 1,396 patients
received a new treatment 1 year after preoperative treatment
and surgery (Pre-Tx, 17.9%): in 189 of these, chemotherapy
was prescribed more than 1 year after surgery (Pre-Sys CTx,
2.4%), whereas 1,207 received a new local treatment (surgery/
surgery and radiotherapy) (Pre-Local Tx, 15.5%).
The CD group was defined as patients who died within 1
year of diagnosis due to rapid clinical deterioration (CD,
1,393 patients; 17.8%). The CD group was divided into five
subgroups according to treatment received: only surgery
(CD-OP, 327 patients; 4.2%), only radiotherapy (CD-RT, 79
patients; 1.0%), pre/postoperative treatment (CD-Pre/Post-
OP, 333 patients; 4.2%), systemic treatment (CD-CTx/CCRT,
299 patients; 3.8%), and patients with no treatment (CD-No
Tx, 355 patients; 4.5%).
5. Survival rates 
The survival curve of each patient group was estimated
using the Kaplan-Meier product-limit estimator method
from diagnosis to death (Fig. 5). The 5-year survival rate after
diagnosis was 56.4% in the total STS group, 82.5% in the loca-
lized STS group, and 27.2% in the advanced STS group. As
expected, the survival rate of advanced STS patients was
lower than that of localized STS patients. Median overall sur-
vival was 8 years in all patients but was only 1.76 years in
the advanced STS group, much shorter than in the localized
STS group (more than 50% of localized STS patients did not
die during the follow-up period, and the median overall sur-
vival was not reached).
When the CD group was re-classified according to the
treatment they received and then analyzed by treatment
modalities, the 5-year survival rates after diagnosis by treat-
ment were 74% for OP+CD-OP, 70.1% for RT+CD-RT, 53.1%
for Pre/Post-OP+CD-Pre/Post-OP, 28.6% for CTx/CCRT+
CD-CTx/CCRT and 0% for CD-No Tx. Advanced STS cases
from the ‘Pre/Post-OP group showed a lower survival rate
than the total Pre/Post-OP group and a higher rate than the
CTx/CCRT group. Median overall survival was 5.73 years
in ‘Pre/Post-OP+CD-Pre/Post-OP’ group, 1.85 years in ‘CTx/
CCRT+CD-CTx/CCRT’ group, and 0.24 years in ‘CD-No Tx’
group. Among the advanced STS, the median survival rate
of the ‘Pre/Post-Tx+CD-Pre/Post-OP’ group was longer
than that of the ‘CTx/CCRT+CD-CTx/CCRT’ group (3.43
years vs. 1.85 years) (Fig. 6). 
6. Analysis of chemotherapy patterns of advanced STS 
patients
Only the initial chemotherapy after diagnosis of the advan-
ced STS patients (n=3,506) in the STS cohort was analyzed.
In total, 2,299 of the advanced STS patients received at least
one chemotherapy treatment after diagnosis (65.6% of the
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Fig. 5.  Kaplan-Meier curve of overall survival. STS, soft
tissue sarcoma.
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STS advanced patient cohort); 657 were included in the
CTx/CCRT group (28.6%), 1,096 in the “Pre-Tx or Post-Tx”
group (47.7%), and 546 belonged to the CD group (23.8%)
(Table 4).
Of the advanced STS patients who underwent chemother-
apy, 1,149 were treated with anthracycline (50.0%). The
largest fraction of patients used doxorubicin plus ifosfamide
(458 patients, 19.9%), followed by paclitaxel (385 patients,
16.8%), others (372 patients, 16.2%), ifosfamide (336 patients,
14.6%), gemcitabine and/or docetaxel (56 patients, 2.4%),
and pazopanib (1 patient, 0.04%). When analyzing those 
patients who received anthracycline-containing chemother-
apy by year, the prevalence of patients receiving anthracy-
cline-containing chemotherapy in a neoadjuvant/adjuvant
or metastatic setting was 229 in 2012, 245 in 2013, and 243 in
2014 (S3 Table).
Among the advanced STS patient subgroups, the chemo-
therapy patterns were slightly different. All patients in the
CTx/CCRT group (657 patients) underwent chemotherapy
after diagnosis, and the most frequently used regimen was
paclitaxel (20.4%), doxorubicin plus ifosfamide (17.2%), and
ifosfamide (13.4%). Among the 1,456 patients in the Pre-Tx
and Post-Tx groups, 1,096 patients (75.3%) received chemo-
therapy at least once after diagnosis. In this group, doxoru-
bicin plus ifosfamide was most frequently used (22.3%),
followed by ifosfamide (15.8%), paclitaxel (14.9%), and
MAID (mesna, doxorubicin, ifosfamide, dacarbazine) regi-
men (12.1%). In the CD group, the percentage of patients
who received doxorubicin plus ifosfamide was 18.5%, 16.1%
received paclitaxel, and 13.7% received ifosfamide. The Pre-
Tx and Post-Tx group had the largest proportion of patients
who received anthracycline-containing chemotherapy (55.9%),
and the lowest number was in the CTx/CCRT group (42.0%).
Discussion
This study, based on the analyses of the NHIS in Korea,
found that about 977 patients are diagnosed with STS every
year in Korea, 45% with advanced STS. The total incidence
of STS has been estimated at 2.49 per 100,000 person-years,
while it stands at 1.37 per 100,000 person-years for localized
STS and 1.12 per 100,000 person-years for advanced STS. The
5-year survival rate was 82.4% for localized STS cases and
27.2% for advanced cases. Almost one out of five patients
(18%) died within 1 year of diagnosis. Most other patients
(32.9% of total) were treated solely with surgery. The first-
line chemotherapy pattern of advanced STS patients after 
diagnosis was anthracycline-containing therapy in about
50% of the cases, followed by paclitaxel (16.8%), ifosfamide
(14.6%), gemcitabine or docetaxel (2.4%), and pazopanib
(0.04%).  
The average age of patients with clinically advanced STS
in our study was 56.1 years, and 53.2 years for localized STS
patients. These figures are slightly lower than those reported
by the Japanese registry (58.3) [15], the Surveillance, Epi-
demiology, and End Results report  (SEER, 58 years) [16] and
for a French cohort (61.5) [17]. Our study showed that the
proportion of patients in the age category 20-40 was 18.6%;
this was higher than in other solid tumors (lung, 1%; liver
cancer, 2%; gastric cancer, 3%; colorectal cancer, 3%; and
breast cancer, 10%). Furthermore, the proportion of patients
with comorbidities in this study (6.4%) was lower than those
reported by Kang et al. (12.9%) [8] and Maretty-Nielsen et al.
(25%) [18]. This might be due to the nature of the data; while
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Fig. 6.  Kaplan-Meier curve of overall survival by treat-
ment modalities in advanced soft tissue sarcoma (STS).
The cases of CD (clinical deterioration < 1 year) were inclu-
ded in the relevant groups according to the modalities.
‘With surgery’ (n=1,789)=‘Pre-Tx’ (n=1,396)+‘Post-Tx’ (n=
60)+‘CD-Pre/Post-OP’ (n=333). ‘Without surgery’ (n=956)
=‘CTx/CCRT’ (n=657)+‘CD-CTx/CCRT’ (n=299). OP, only
surgery; CTx/CCRT, chemotherapy±radiotherapy; Pre-
Tx, patients who received surgery with preoperative treat-
ment followed by any treatment for cancer (chemothe-
rapy, radiotherapy, or surgery) 1 year after the initial sur-
gery; Post-Tx, patients who received surgery with postop-
erative treatment followed by any treatment for cancer
(chemotherapy, radiotherapy, or surgery) 1 year after the
initial surgery; CTx/CCRT, patients who received only
chemotherapy with or without radiotherapy.
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our study is based on claim data, the Kang et al. [8] and
Maretty-Nielsen et al.'s [18] studies were based on medical
chart reviews of patients who underwent surgery for extrem-
ity STS and cancer registry analysis, respectively. 
The total incidence of STS in our analyses of Korea (2.49
per 100,000 person-years) is within the reported incidences.
The incidence is lower when compared with the incidence
rates of some countries or regions, for example the United
States (4.2 per 100,000 person-years) [19], Europe (4.7 per
100,000 person-years) [6], Ireland (4.48 per 100,000 person-
years) [20] and the United Kingdom (4.51 per 100,000 per-
son-years) [21]. However, the incidence is higher than the
incidence rate reported for Sweden (1.8 per 100,000 person-
years) [22] and Beijing (1.15 per 100,000 person-years) [23].
The incidence rates in our study are also higher than the 
estimated rate for Korea in the report by the International
Association of Cancer Registries in five continents. The esti-
mated incidence from 2003 to 2007 was 1.6 per 100,000 per-
son-years in males and 1.2 per 100,000 person-years in
females [24]. However, this last report only includes ICD-10
diagnosis C47 and C49, and they do not report C48, C223,
C224, or C542 cases. As a matter of fact, some of the discrep-
ancies in the incidence of STS across countries are due to the
different diagnoses included in these studies. Bearing this in
mind, it would be advisable to reach consensus on the estab-
lishment of consistent codes for STS to enable international
comparisons. Our results showed that, after 2010, the inci-
dence of localized STS increased more steeply than that of
advanced STS. A possible explanation may be the early detec-
tion of cancer due to technological advances in imaging such
as positron emission tomography and abdominopelvic com-
puted tomography. Additionally, active workup of other dis-
eases such as gastric cancer or colorectal cancer might have
contributed to earlier detection of STS, even when asympto-
matic. 
Regarding anatomical location at the time of diagnosis, the
advanced STS ratios at C47 and C49 were 43% and 39%, res-
pectively, while the advanced STS ratio at C48 was 58%. C47
and C49 are associated with extremity STS, and early detec-
tion and treatment are relatively easy, whereas C48 is located
Table 4.  Initial chemotherapy treatment for advanced STS patients
Chemotherapy Advanced STS CTx/CCRT Post-Tx or    CDPre-Txa)
Total cohort 3,506 ( 657 ( 1,456 ( 1,393 (
Systemic therapy cohort 2,299 (100) 657 (100) 1,096 (100) 546 (100)
Anthracycline-containing regimen 1,149 (50.0) 276 (42.0) 613 (55.9) 260 (47.6)
Doxorubicin monotherapy 249 (10.8) 60 (9.1) 127 (11.6) 62 (11.4)
Epirubicin monotherapy 4 (0.2) 2 (0.3) 1 (0.1) 1 (0.2)
Doxorubicin+ifosfamide 458 (19.9) 113 (17.2) 244 (22.3) 101 (18.5)
Epirubicin+ifosfamide 21 (0.9) 6 (0.9) 8 (0.7) 7 (1.3)
CYVADIC regimen 109 (4.7) 21 (3.2) 64 (5.8) 24 (4.4)
MAID regimen 215 (9.4) 36 (5.5) 133 (12.1) 46 (8.4)
Other doxorubicin-containing 93 (4.1) 38 (5.8) 36 (3.3) 19 (3.5)
Ifosfamide 336 (14.6) 88 (13.4) 173 (15.8) 75 (13.7)
Paclitaxel 385 (16.8) 134 (20.4) 163 (14.9) 88 (16.1)
Gemcitabine and/or docetaxel 56 (2.4) 21 (3.2) 20 (1.8) 15 (2.8)
Pazopanib 1 (0.0) 0 ( 0 ( 1 (0.2)
Others 372 (16.2) 138 (21.0) 127 (11.6) 107 (19.6)
Values are presented as number (%). More than two were prescribed out: CYVADIC regimen, cyclophosphamide, vincristine,
dacarbazine; MAID, In the case of prescribing one of (1) doxorubicin and dacarbazine, (2) ifosfamide and dacarbazine, or (3)
doxorubicin and ifosfamide and dacarbazine. STS, soft tissue sarcoma; CTx/CCRT, patients who received only chemotherapy
with or without radiotherapy; Post-Tx, patients who received surgery with preoperative treatment followed by any treatment
for cancer (chemotherapy, radiotherapy or surgery); Pre-Tx, patients who received surgery with postoperative treatment
followed by any treatment for cancer (chemotherapy, radiotherapy or surgery); Post-Sys CTx, Post-Tx patients who received
systemic chemotherapy; Pre-Sys CTx, Pre-Tx patients who received systemic chemotherapy. a)Among Post-Sys CTx or Pre-
Sys CTx patients, frequency of medication used as first line: doxorubicin monotherapy 19 patients, doxorubicin and ifos-
famide 45 patients, epirubicin and ifosfamide 1 patient, CYVADIC regimen 11 patients, MAID regimen 23 patients, other
doxorubicin containing 9 patients, ifosfamide 24 patients, paclitaxel 34 patients, gemcitabine or doxetaxel 4 patients, others
26 patients. 
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in the peritoneum or retroperitoneum, which makes early
detection difficult, and even if it is found, surgical treatment
options are limited. Thus, clinical characteristics might 
explain the relatively higher ratio of advanced STS at C48. 
The overall 5-year survival rate of the STS patient cohort
after diagnosis was 56.4%, which was similar to that reported
by other countries: Ireland (56%, 1994-2011) [20] and the
United Kingdom (55%, 2006-2010) [21]; close to the European
average (57.8%, 2000-2002) [6] but lower than in the United
States (65%, 2006-2012) [25] and Japan (77.5%, 2006-2012)
[15]. It should be noted that the Japanese study reported dis-
ease-specific survival rates. Considering its definition, in gen-
eral, the disease-specific survival rate is higher than the
overall survival rate. The overall 5-year survival rate accord-
ing to disease status was 82.5% in localized STS and 27.2%
in advanced STS. This is comparable to the 83% for localized
sarcoma and 16% for distant sarcoma reported in the United
States, according to the SEER data [16]. The median overall
survival rate of the total STS group was 8 years whereas it
was 1.76 years for the group with advanced STS. This low
median overall survival rate for advanced STS was similar
to rates reported in previous studies (i.e., 1.17, Germany;
1.50, France, and 1.69, the United Kingdom) [17,26,27]. It sug-
gests that advanced STS is a serious disease and that new
treatment methods to improve the odds of survival are
greatly needed. 
The patterns of chemotherapy in advanced STS patients
were also analyzed. Of those with advanced STS, a total of
2,299 patients (65.6%) received chemotherapy. This was sig-
nificantly higher than the 26.1% reported in Japanese studies
[15]. Of the 2,299 patients who underwent chemotherapy,
41.6% (956 patients) received it in palliative settings, while
in the Japanese study this was 28.9%. The proportion of pati-
ents with metastatic disease at the time of diagnosis was sim-
ilar in Korea (12.2%) and Japan (11.4%). The proportion of
surgical treatment was 67.7% and 80.6%, respectively. Most
STS patients are treated by orthopedic surgeons in Japan and
this clinical practice situation might contribute to the differ-
ence in treatment pattern.
Anthracycline-based chemotherapy is recommended as a
standard-of-care in palliative settings in well-known guide-
lines such as the National Comprehensive Cancer Network
(NCCN) and the European Society of Medical Oncology
(ESMO). In this study, anthracycline-based chemotherapy
was the most frequent treatment for advanced STS (50%),
which is consistent with previous studies from other coun-
tries such as Germany, the United Kingdom and Australia
[26-28]. However, when analyzed by specific regimen, dox-
orubicin plus ifosfamide (AI) combination therapy was the
most frequently used, whereas doxorubicin monotherapy
was most frequently used in Germany, the United Kingdom,
and Australia [26-28]. Pazopanib and gemcitabine +/– doc-
etaxel use were only 0.04% and 2.44%, respectively, which is
much lower than in other countries. This might be because
pazopanib received national reimbursement approval in July
2013 and gemcitabine +/– docetaxel was only used in some
hospitals with pre-approval for off-label use of this regimen
in Korea. Regimens in the advanced STS subgroup showed
a higher percentage of AI, MAID, and CYVADIC regimen in
the Pre/Post-Tx subgroup compared with the CTx/CCRT
subgroup. Considering the fact that the Pre/Post-Tx group
consists of patients who could receive surgical resection at
the time of diagnosis, the clinical practice custom that com-
bination therapies with a higher response rate were preferred
may be reflected in this result. Compared with single-agent
chemotherapy, combination chemotherapy seems to work
well in terms of tumor response rate and progression-free
survival but there seems to be no difference in overall sur-
vival in other clinical trials [4,29]. In the clinical trial that com-
pared doxorubicin monotherapy with the combination of
“doxorubicin plus olaratumab,” the combined therapy demon-
strated a statistically significant improvement in overall sur-
vival, resulting in a 50% reduction of the hazard ratio [30]. 
Several limitations should be considered when evaluating
these results. First, as our study is based on claim data, the
limitation of all claim databases can be applied. Clinical data
were limited because the primary purpose of claim data is
reimbursement and not research. Consequently, localized/
advanced STS were distinguished based on the modalities
patients actually received rather than disease-stage informa-
tion. For example, we considered patients who received a
new treatment for longer than 1 year as advanced STS cases.
As most adjuvant chemotherapy and/or radiotherapy are
completed within 1 year and the majority of recurrence 
occurred before 1.5 years [31,32], patients with the long treat-
ment are likely to be the recurrent/relapsed cases. Further
study is needed through linkage with the Korean Central
Cancer Registry (KCCR) database that includes information
on histology and stage. Second, when comparing our results
with other studies, we should take into account that STS is a
heterogeneous group of tumors and there is lack of consis-
tency in classification and inclusion/exclusion criteria for
each country. Finally, our study excluded patients with mul-
tiple primary cancer, which might have led to a possible 
underestimation of STS incidence. 
To our knowledge, this is the first study conducted in Korea
to investigate STS epidemiological and clinical characteristics
and treatment patterns by analyzing the Korean NHIS Data-
base that covers almost the entire Korean population. These
results can be used as fundamental data to improve clinical
outcomes in Korean STS patients since they not only provide
information on current STS cancer incidence in Korea but
also on actual clinical practices.  
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